Daptomycin dosing based on ideal body weight versus actual body weight: comparison of clinical outcomes. - Wikidata - awgldk - TriplyDB

Daptomycin dosing based on ideal body weight versus actual body weight: comparison of clinical outcomes.

Daptomycin dosing based on ideal body weight versus actual body weight: comparison of clinical outcomes.

http://www.wikidata.org/entity/Q37544510

about

Antimicrobial Stewardship Intervention and Feedback to Infectious Disease Specialists: A Case Study in High-Dose Daptomycin.Impact of hospital guideline for weight-based antimicrobial dosing in morbidly obese adults and comprehensive literature review.Top 1% of Inpatients Administered Antimicrobial Agents Comprising 50% of Expenditures: A Descriptive Study and Opportunities for Stewardship Intervention.Comprehensive Guidance for Antibiotic Dosing in Obese Adults.Effect of Daptomycin Dose on the Outcome of Vancomycin-Resistant, Daptomycin-Susceptible Enterococcus faecium Bacteremia.

P2860

Q36683458-4D50203B-5148-4B0C-B160-EA0516B72D8F Q38247400-D5E069D7-6B93-4C9C-AE7A-368EDCC465DD Q39029242-CA8C1F06-C5B5-4266-A484-ECA51B032A1C Q40067964-F81BEDB1-A5F1-4F0D-9215-B4D9E4F8FC30 Q40280282-2175C659-E0CA-49CC-8471-F928617ED5DC

P2860

Daptomycin dosing based on ideal body weight versus actual body weight: comparison of clinical outcomes.

http://www.wikidata.org/entity/Q37544510

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 21 October 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Daptomycin dosing based on ide ...... mparison of clinical outcomes.

@en

Daptomycin dosing based on ide ...... mparison of clinical outcomes.

@nl

type

label

Daptomycin dosing based on ide ...... mparison of clinical outcomes.

@en

Daptomycin dosing based on ide ...... mparison of clinical outcomes.

@nl

prefLabel

Daptomycin dosing based on ide ...... mparison of clinical outcomes.

@en

Daptomycin dosing based on ide ...... mparison of clinical outcomes.

@nl

P1433

Q37544510-900468F4-3C66-4B56-9BC8-69C244673C5A

P1476

Q37544510-34C42C1F-31F5-4B07-8C59-34DA2DACC2C4

P2093

Q37544510-31E21104-E45E-419D-B4FF-144A0BA6FDAC

Q37544510-37A3A305-0EB0-4B7A-8B91-B4017598DEFF

Q37544510-448BF29D-49F5-469E-9B7C-ED64855596F6

Q37544510-60E62F31-7107-4880-94C1-F2BA712500FA

Q37544510-8403D296-4183-48E5-A44D-75C822E802A4

Q37544510-CEA136A8-70AE-40D8-A867-74C36BE3A7A9

P2860

Q37544510-1920B8B4-CA61-4CB1-946D-1E24BAA1AD19

Q37544510-20DDCD54-C103-45E9-9174-EF007754A41E

Q37544510-2A361A45-A4F0-4056-9664-31E515851333

Q37544510-2FF427E2-61E6-4586-8FB6-7D06EAFF7A7F

Q37544510-68DEC4A5-CB0F-4E1D-9F5E-7DCA7ABC65EC

Q37544510-75ED8B95-5BC2-44BF-8E5E-B6A543E85C71

Q37544510-A61730A0-7AEE-4073-AC26-8878F03CAFEB

Q37544510-AD4CC7F4-B9E0-465B-B340-4E28AFCA45F7

Q37544510-B409936D-F50C-451E-8FA9-6D109559598D

Q37544510-B515DA76-44F2-4981-BC5B-C84E9B1AC481

P304

Q37544510-7DA94990-5DE4-4120-809E-52EFD6264106

P31

Q37544510-13E26AC4-B82C-448B-A7FF-2795DDCA0FAC

P356

Q37544510-998F7678-92D3-4A12-B665-F7F82A43DE93

P407

Q37544510-B822630A-6D0B-4B6F-822C-717F400E3260

P433

Q37544510-1AED01DE-86B5-45A0-93B9-6809A26273B4

P478

Q37544510-FEE123E2-B723-414A-AE98-D0DF07ADB268

P50

Q37544510-022E0567-9A31-429C-A457-EBAB4FBBDA05

P577

Q37544510-3C0FDDE2-1840-4E95-A753-963AA5C64FD9

P698

Q37544510-D8679EC5-71ED-4846-930A-B29B9FA16BA4

P932

Q37544510-DF73FFE5-BE77-4BD2-9341-4BDCE28A522D

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Daptomycin dosing based on ide ...... omparison of clinical outcomes

@en

P2093

Barry C Fox

http://www.w3.org/2001/XMLSchema#string

Jeffrey T Fish

http://www.w3.org/2001/XMLSchema#string

Jennifer K Ng

http://www.w3.org/2001/XMLSchema#string

Kevin A Buhr

http://www.w3.org/2001/XMLSchema#string

Lucas T Schulz

http://www.w3.org/2001/XMLSchema#string

Warren E Rose

http://www.w3.org/2001/XMLSchema#string

P2860

Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers

Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis.

Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects.

In vivo pharmacodynamic activity of daptomycin

Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers

Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin.

High-dose daptomycin in documented Staphylococcus aureus infections.

Implementation of an antimicrobial stewardship pathway with daptomycin for optimal treatment of methicillin-resistant Staphylococcus aureus bacteremia.

Clinical outcomes of patients receiving daptomycin for the treatment of Staphylococcus aureus infections and assessment of clinical factors for daptomycin failure: a retrospective cohort study utilizing the Cubicin Outcomes Registry and Experience.

The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects.

P304

88-93

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.01018-13

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

58

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-10-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24145531

http://www.w3.org/2001/XMLSchema#string

P932

3910783

http://www.w3.org/2001/XMLSchema#string